Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience Investigation

AstraZeneca1,634 enrolled

Overview

The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with non-steroidal anti-inflammatory drug (NSAID).

Nexium capsules Specific Clinical Experience Investigation for long-term use concerning prevention of recurrence of gastric ulcer or duodenal ulcer with NSAIDs

Study Type

OBSERVATIONAL

Enrollment

1,634

Conditions

Gastric Ulcer Duodenal Ulcer

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: -Patients who are given NSAIDs for long terms to control pain due to disease such as rheumatoid arthritis and osteoarthritis, and given Nexium to suppress recurrence of gastric ulcer or duodenal ulcer. Exclusion Criteria: * Patients having gastric ulcer/duodenal ulcer when Nexium is started (Active phase (A1, A2) or healing phase (H1, H2) of Sakita-Miwa classification on endoscopy) * Patients who had been given Nexium for suppression of recurrence of gastric ulcer/duodenal ulcer.

Locations (46)

Outcomes

Primary Outcomes

Number of Adverse Drug Reactions

Adverse event incidence

Time frame: 1 Year

Secondary Outcomes

Non-recurrence rate of peptic ulcer

Time frame: 1 Year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

Aichi, Japan

Research Site

Akita, Japan

Research Site

Aomori, Japan

Research Site

Chiba, Japan

Research Site

Ehime, Japan

Research Site

Fukui, Japan

Research Site

Fukuoka, Japan

Research Site

Fukushima, Japan

Research Site

Gifu, Japan

Research Site

Gunma, Japan

...and 36 more locations